Connect with us

Press Releases

Study Finds Significantly More Adults Living With Diabetic Retinopathy in the United States Than Previously Estimated

New study finds that nearly 10 million people in the US with diabetes have diabetic retinopathy.

mm

Published

on

Study Finds Significantly More Adults Living With Diabetic Retinopathy in the United States Than Previously Estimated

(PRESS RELEASE) CHICAGO — A new study published today in JAMA Ophthalmology, “Prevalence of Diabetic Retinopathy in the US in 2021,” found that in 2021, an estimated 9.6 million people in the United States (26.4 percent of those with diabetes) had diabetic retinopathy (DR), and 1.84 million people (5.1 percent of those with diabetes) had vision-threatening diabetic retinopathy (VTDR). The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004. VTDR has also almost doubled since last estimated in 2004.

The study is the first of its kind to estimate the prevalence of DR and VTDR in people younger than 40 years. In the youngest age group, ages 0 to 24 years, more than 1 in 10 people with diabetes had DR, which increased to nearly 1 in 5 among people with diabetes ages 25 to 39 years.

Diabetic retinopathy occurs when small blood vessels leak and bleed in the retina. The retina is the layer of cells lining the back wall inside the eye that senses light and sends signals to the brain for vision. Early detection and treatment can reduce the risk of vision loss from this potentially blinding eye disease.

The ‘Prevalence of Diabetic Retinopathy in the US in 2021’ study was authored by researchers from the Centers for Disease Control and Prevention’s (CDC) Vision Health Initiative, NORC at the University of Chicago (NORC), and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington (Seattle), with support from Prevent Blindness, the nation’s oldest eye health and safety nonprofit organization.

“The national increase of diabetes over the last two decades has likely impacted the number of people living with serious complications like diabetic retinopathy,” said CDC epidemiologist Elizabeth Lundeen, PhD, MPH. “This study provides new state and county level prevalence estimates that the health care and public health communities can use to inform screening and early interventions for optimal vision health.”

Abraham Flaxman, PhD, added: “In this work, we brought together data from all the relevant sources in the CDC’s Vision and Eye Health Surveillance System to triangulate between multiple measurements and make estimates that no single source could provide alone.”

Advertisement

Additional key findings from the study include:

  • Approximately 1 in 4 Americans ages 40 and older with diabetes have DR.
  • These new estimates include the prevalence of DR and VTDR in people younger than age 40 years. Past prevalence estimates were only for the US population aged 40 and older.
  • VTDR prevalence rates are higher for Black (8.7 percent) and Hispanic (7.1 percent) individuals than White individuals (3.6 percent). Thus, a higher percentage of Black and Hispanic individuals with diabetes are at risk for vision loss compared to their White counterparts.
  • The prevalence of both DR and VTDR varied widely by U.S. state and county. After standardizing by age, sex/gender, and race/ethnicity, rates of DR among persons with diabetes ranged from a low of 21.2 percent in Nevada to a high of 34.2 percent in Hawaii.
  • Prevalence of DR and VTDR among people with diabetes increased substantially with age but then decreased in the older age groups, likely because DR and VTDR are markers for more severe diabetes, which can lead to early mortality.

“This study demonstrates the value of vision surveillance, which allows us to monitor emerging trends in vision threatening conditions like diabetic retinopathy,” said David B. Rein, Ph.D., Program Area Director for NORC at the University of Chicago’s Public Health Analytics Program and one of the study’s co-authors. “The information provided in this study can be used at the national, state, and county level to understand the burden of diabetic retinopathy and to design interventions to help people living with the condition preserve their vision.”

Study estimates were developed using data from CDC’s Vision and Eye Health Surveillance System (VEHSS). The VEHSS leverages new and existing data sources to help health professionals, researchers, policy makers, and patients understand the scope of vision loss, eye disorders, and eye care services in the United States. Detailed estimates of DR and VTDR at the national-, state-, and county-level stratified by age group, sex/gender, and race/ethnicity can be accessed online at the VEHSS website.

Prevent Blindness serves as an education and communications partner for the VEHSS. For diabetes patients and their care partners, Prevent Blindness offers a wide variety of user-friendly resources in English and Spanish, including downloadable fact sheets, patient educational videos, and a listing of eye care financial assistance resources.

For healthcare professionals, community health educators, and diabetes educators, Prevent Blindness provides the newly redesigned Diabetes + The Eyes educational toolkit. This free program includes an educator course with PowerPoint presentations and scripts, fact sheets, and social media graphics.

“The number of diabetes cases in America continues to grow, and with that, so are the damaging effects on vision,” said Jeff Todd, president, and CEO of Prevent Blindness. “It is our hope that this new data will guide us to successful interventions and improved outcomes for those with diabetes and their families.”

Advertisement

For more information on the “The Prevalence of Diabetic Retinopathy in the United States In 2021” study or the VEHSS, visit here. Or visit the Prevent Blindness page here.

For information on diabetes-related eye diseases, visit here.

SPONSORED VIDEO

With Crizal you can have it all!

Patients expect clarity of vision, scratch resistance, anti-glare technology, easy-to-clean lenses, and UV protection from their lenses. Crizal Sapphire HR is the latest generation of anti-reflective coating that combines our innovative technologies, 360 Multi-angular Technology™, High-Resistance Technology™, High Surface Density Process™ into one coating to deliver best in class performance. Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR shield the lenses against reflections, scratching, smudging and UV light for long-lasting transparency, durability, and protection. Crizal coatings can be applied to any design, including traditional single vision, Eyezen®, Eyezen+ and Varilux®! Widely available across lab networks and through all major managed vision care providers today. Crizal Saphire HR benefits include: • 360 Multi-angular Technology™ that cuts front and lateral backside reflection • High-Resistance Technology™ that offers the best combination of scratch and smudge resistance • High Surface Density Process™ that ensures the lense is easy-to-clean, smudge resistant and water repellent For more information about Crizal Saphire HR, go here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular